News
Largest DACH acquisition in the greeting card segment to date
11. April 2023
GOLDBEK Holding GmbH, a fast growing and innovative German greeting card publishing company, acquires 100% of ABC Kunst- und Glückwunschkartenverlag (legal name: A. Boss & Co AG), a privately owned Swiss market leader in printing, publishing and trading of greeting cards and other graphic products.
GOLDBEK Holding GmbH’s position within the printing and greeting cards sector in the DACHregion is further
strengthened and expanded through the acquisition of A. Boss & Co AG.
BGPartner assisted GOLDBEK Holding GmbH in the negotiations and advised them on all Swiss legal matters regarding this M&A transaction. The team of BGPartner was led by Oliver Gnehm (Partner) and further consisted of Thomas Gysin (Senior Associate).
More information about our negotiation expertise can be found here.
New team members
03. April 2023
BGPartner is pleased to welcome David Dalla Vecchia (Attorney-at-law at the Zurich office) and Anja Spahni (Trainee at the Berne office)
as of April 1, 2023. Further information on our entire team can be found here.
Interested in how Swiss executives negotiate?
31. March 2023
BGPartner and the Negotiation Academy Potsdam of the Universität Potsdam wanted to find out and conducted the first comprehensive and representative study on this topic, with answers from more than 350 Swiss executives. A study with many insights and practical relevance and on how negotiations are conducted. The study “How do Swiss executives negotiate?” will be released on May 25, 2023. Mark your calendar!
Vis Moot Court Trial Round 2023
13. March 2023
This year we had the privilege of hosting the teams of Universität Bern, Université de Genève and University Zürich who did an outstanding job with their pleadings.
Find out in the After Movies what the students benefited most from, how realistic a trial round is, what the preparation looks like and why BGPartner continues to support this project.
After Movie (Office Berne) Universität Bern vs. Universität Genf
BGPartner advises co-lead investors Forbion and Jeito Capital in USD 112 millions Series B financing round of Noema Pharma Ltd
07. March 2023
Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS) disorders, successfully closed an oversubscribed Series B financing round, raising CHF 103 millions (approx. USD 112 millions).
The round was co-led by the European healthcare focused investment firms Forbion and JEITO Capital. UPMC Enterprises and an additional new investor joined existing investors Sofinnova Partners, Polaris Inc., Gilde Healthcare and The Invus Group to complete the round.
The proceeds of the Series B financing will be used to advance Noema Pharma’s clinical-stage assets. Following the closing of this Series B financing round, Nanna Lüneborg from Forbion and Rachel Mears from Jeito Capital will join the board of directors of Noema Pharma Ltd.
BGPartner advised co-lead investors Forbion and Jeito Capital on all Swiss legal matters and the negotiations of this Series B financing round. The core team consisted of Oliver Gnehm (Partner) and Victoria Marty (Associate) and furthermore comprised Olivier Bula (Partner), Fabiola Weilenmann-Anthamatten (Managing Associate) and Geremia Stüssi (Jurist).
More information can be found here.